Vaxart (NASDAQ:VXRT) announced its earnings results on Sunday. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.04), Briefing.com reports. The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.62 million. Vaxart had a negative return on equity of 84.90% and a negative net margin of 281.50%. The firm’s revenue was down 82.8% on a year-over-year basis.
NASDAQ:VXRT traded up $0.73 during mid-day trading on Tuesday, hitting $8.75. The stock had a trading volume of 1,307,073 shares, compared to its average volume of 18,688,678. Vaxart has a twelve month low of $2.23 and a twelve month high of $24.90. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -15.19 and a beta of -0.11. The company’s 50 day simple moving average is $6.40 and its 200 day simple moving average is $6.87.
VXRT has been the subject of a number of research analyst reports. B. Riley reaffirmed a “buy” rating and issued a $13.00 target price (down from $16.00) on shares of Vaxart in a research note on Thursday, March 4th. Zacks Investment Research downgraded shares of Vaxart from a “hold” rating to a “sell” rating in a research note on Tuesday, March 9th.
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection.
Recommended Story: Calculating net profit and net profit margin ratio
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.